We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Btg Plc | LSE:BTG | London | Ordinary Share | GB0001001592 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 840.00 | 839.00 | 840.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
15/11/2016 11:54 | Not sure on one of the last FX points. Yes BTG stand to gain on dollar vs sterling revenue movements but my understanding is the impact of adverse foreign exchange contracts will still be with us. It will take six six months to a year to be free of these things. The FX annual charge is likely to be £25m vs £17m at the interim stage. Getting smaller certainly. BTG presented a few scaled proviso's re these currency movements but nothing to change the scenario significantly, that I can see. So some bright BTG financial spark undertook some chunky forward FX commitments and got it wrong. As you say the business is trundling along and I cannot disagree..Having said that, BTG presented quite an upbeat operational growth message for the next few years The CEO still holds to the 2021 revenue targets and said if you do the maths of the double digit revenue compounding you can get there. Also there are a multiple of revenue growth ways that this target can be reached. It was also said that the 2021 figure was a figure within a period but yearly double digit growth was likely to be seen for the next ten years. A few bolt on IM acquisitions are also possible as the company gears up in the growth IM market. The exc's( FD) say it is easy to see that they could have a £200 to £300m war chest including reinvesting strong cash flows (my words here!) to hand ,if the opportunities presented themselves. Varithena, they suggest, has turned the corner and, as an early stage project, they sounded a bit more positive and then slipped in the 2018 suggested timescale for the permanent CPT code. So that has slipped a bit although an increasing number of insurers are happy to pay up on the interim generic CPT code. Getting there but slowly! | gregmorg | |
15/11/2016 11:08 | "Excluding the effects of foreign exchange losses on forward contracts in the current period, adjusted basic EPS would have increased by 19%.IFRS basic EPS was 3.4p (H1 2015/16: 13.4p), down 75% on the same period last year, due to the effect of foreign exchange losses on forward contracts and the settlement with the US government in respect of the investigation into the historic marketing of LC Bead(R) ."It would appear that things are trundling along.They're implying that they are now benefitting from FX movements.We're used to Varientha making slow progress,no change there.Good cash flow generation.Unfortuna | steeplejack | |
15/11/2016 10:33 | £5?? Perhaps you want to read the RNS again | sandeep67 | |
15/11/2016 08:36 | Without intending to disagree with the few posts above I prefer to wait until the end of the week to assess what the market really thinks. My own view is that this is not all that we hoped for but I think I will hold without much concern. If they do fall to £5 I will add. | jadeticl3 | |
15/11/2016 08:27 | The newsletter that suggested last week that buying BTG ahead of the results is now looking a bit foolish. Selling by disgruntled speculators probably accounts for some of the rout this morning. That, and the fact that today's results are the first time (as far as I am aware) that BTG have confirmed when the Zytega and Lemtrada royalties end. We all knew it was coming though. Although it will be painful, a fall to £5 would provide a great opportunity to top-up. | spyder | |
15/11/2016 08:19 | A close today below 610p will be a problem for us. | spyder | |
15/11/2016 08:18 | I did try being the voice of reason, but certain characters are just plain rude! Goodbye. | cockneytrader | |
15/11/2016 08:15 | The market seems to agree with CT, so far ... | spyder | |
15/11/2016 07:41 | Only because of the fine no doubt.Solid results . FRS Operating Profit was GBP29.1m (H1 2015/16: GBP44.2m), down 34%. IFRS Operating Profit was down on last year as a result of the one-time charge of GBP28.0m on settlement of the US government investigation into the marketing of LC Bead(R) , and higher intangible asset amortisation of GBP19.9m (H1 2015/16: GBP17.2m), the increase due to the intangible assets acquired with Galil. | bargainbob | |
15/11/2016 07:40 | Read the report. EPS down 75%! | cockneytrader | |
15/11/2016 07:39 | Number of physician up greatly , the ramp up to the tipping point. Shocking it is happening faster than I expected. | bargainbob | |
15/11/2016 07:37 | Really is posting "Double-digit revenue growth drives strong first half performance" | bargainbob | |
15/11/2016 07:35 | Varithena sales up 425%!! Wohoo, happy days! ;-) | spyder | |
10/11/2016 13:07 | That's my boy! | fhmktg | |
10/11/2016 12:50 | Varithena s the best thing since sliced bread | bargainbob | |
10/11/2016 08:50 | Just give us some encouraging news on Varithena.....pretty please!! | fhmktg | |
09/11/2016 15:11 | Any company able to demonstrate real positive health outcomes AND cost savings will prosper in the new environment.....soun | fhmktg | |
09/11/2016 15:08 | I'm sure that for $10,000 you can have five minutes in the locker room! | fhmktg | |
09/11/2016 14:43 | If he does, he would doubtless treat the condition with Viagra. | harijan | |
09/11/2016 14:29 | This, from Woodford's latest communication to WPCT shareholders (this morning),says it all: "Clearly, our significant weighting towards the health care industry has weighed on performance for much of the year, as the market has fretted about the prospect of a Clinton presidency and what that may mean for drug pricing. Now the outcome is known, the prospect of drug pricing legislation is off the agenda. Meanwhile, in California, proposition 61 which would have limited the price of prescription drugs in the State, has been voted down. From a sentiment perspective at least, the news should be positive for this important part of the portfolio." Here in the USA there is a profound sense of shock at the result on one side: on the other, there are already signs of a vengeful jubilation. I wonder if Trump has Varicose Veins......... | muffmitz | |
09/11/2016 12:02 | See! What did I tell you? No Clinton and BTG shoots up! An obvious relief rally. No doubt, however, that the usual suspects will, as ever, take advantage of all the disruption and push it down again. But it won't be 'Varithena' that causes it. | harijan |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions